{"title":"www.PDtrials.org:通过互联网提高帕金森氏症临床试验意识","authors":"","doi":"10.1016/j.nurx.2006.05.034","DOIUrl":null,"url":null,"abstract":"<div><p><em>PDtrials<sup>⁎</sup></em> is a national initiative dedicated to increasing education and awareness about clinical research by providing information to help people with Parkinson’s learn and make informed decisions about participating in clinical trials. <span>www.PDtrials.org</span><svg><path></path></svg> is a first-of-its-kind website that lists over 50 clinical studies seeking participants. It sees over 25,000 visits per month and has an email list of close to 2,500.</p><p><em>PDtrials</em> was initiated in response to a concern within the Parkinson’s community about the low levels of awareness and participation in clinical research. As many as one million people in the U.S. live with Parkinson’s yet less than one percent participate in clinical studies—far short of volunteers that researchers anticipate will be needed over the next two to three years.</p><p>In October 2005, the <em>PDtrials</em> campaign initiated a series of online marketing strategies to increase visibility for <span>www.PDtrials.org</span><svg><path></path></svg>. These included the development of a monthly HTML email newsletter—the <em>PDtrials</em> Bulletin and engaging in “viral” marketing, such as forwarding the <em>PDtrials Bulletin</em> to contacts throughout the community.</p><p>The results were an increase in average daily visitors from 465 in September 2005 to 822 in January 2006 and an increase in overall visits from 13,956 in September 2005 to 25,506 in January 2006. In addition, over 50% of <em>PDtrials Bulletin</em> recipients opened the email and clicked through from the <em>Bulletin</em> to <span>www.PDtrials.org</span><svg><path></path></svg>. This compares with a nonprofit industry standard of a 30% open rate and 3% click-through rate.</p><p>Various strategies have been employed to increase web traffic to <span>www.PDtrials.org</span><svg><path></path></svg>. The greatest success has been through online cultivation of individuals who have requested to receive information about clinical studies and who are thought to be interested.</p><p>*<em>PDtrials</em><span> is led by the Parkinson’s Disease Foundation in collaboration with the American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson’s Research, the National Parkinson Foundation, the Parkinson’s Action Network, The Parkinson Alliance and WE MOVE. The campaign is advised by the National Institute of Neurological Disorders and Stroke (NIH), the Parkinson Study Group, the Parkinson Pipeline Project and the Parkinson’s Institute.</span></p></div>","PeriodicalId":87195,"journal":{"name":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","volume":"3 3","pages":"Page 415"},"PeriodicalIF":0.0000,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.nurx.2006.05.034","citationCount":"0","resultStr":"{\"title\":\"www.PDtrials.org: Increasing Parkinson’s Clinical Trial Awareness through the Internet\",\"authors\":\"\",\"doi\":\"10.1016/j.nurx.2006.05.034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><em>PDtrials<sup>⁎</sup></em> is a national initiative dedicated to increasing education and awareness about clinical research by providing information to help people with Parkinson’s learn and make informed decisions about participating in clinical trials. <span>www.PDtrials.org</span><svg><path></path></svg> is a first-of-its-kind website that lists over 50 clinical studies seeking participants. It sees over 25,000 visits per month and has an email list of close to 2,500.</p><p><em>PDtrials</em> was initiated in response to a concern within the Parkinson’s community about the low levels of awareness and participation in clinical research. As many as one million people in the U.S. live with Parkinson’s yet less than one percent participate in clinical studies—far short of volunteers that researchers anticipate will be needed over the next two to three years.</p><p>In October 2005, the <em>PDtrials</em> campaign initiated a series of online marketing strategies to increase visibility for <span>www.PDtrials.org</span><svg><path></path></svg>. These included the development of a monthly HTML email newsletter—the <em>PDtrials</em> Bulletin and engaging in “viral” marketing, such as forwarding the <em>PDtrials Bulletin</em> to contacts throughout the community.</p><p>The results were an increase in average daily visitors from 465 in September 2005 to 822 in January 2006 and an increase in overall visits from 13,956 in September 2005 to 25,506 in January 2006. In addition, over 50% of <em>PDtrials Bulletin</em> recipients opened the email and clicked through from the <em>Bulletin</em> to <span>www.PDtrials.org</span><svg><path></path></svg>. This compares with a nonprofit industry standard of a 30% open rate and 3% click-through rate.</p><p>Various strategies have been employed to increase web traffic to <span>www.PDtrials.org</span><svg><path></path></svg>. The greatest success has been through online cultivation of individuals who have requested to receive information about clinical studies and who are thought to be interested.</p><p>*<em>PDtrials</em><span> is led by the Parkinson’s Disease Foundation in collaboration with the American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson’s Research, the National Parkinson Foundation, the Parkinson’s Action Network, The Parkinson Alliance and WE MOVE. The campaign is advised by the National Institute of Neurological Disorders and Stroke (NIH), the Parkinson Study Group, the Parkinson Pipeline Project and the Parkinson’s Institute.</span></p></div>\",\"PeriodicalId\":87195,\"journal\":{\"name\":\"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics\",\"volume\":\"3 3\",\"pages\":\"Page 415\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.nurx.2006.05.034\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1545534306001040\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1545534306001040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
PDtrials是一项国家倡议,致力于通过提供信息来帮助帕金森患者学习和做出参与临床试验的明智决定,从而提高对临床研究的教育和认识。www.PDtrials.org是首个此类网站,上面列出了50多项寻求参与者的临床研究。它每月的访问量超过2.5万次,电子邮件列表接近2500封。pd试验的启动是为了回应帕金森社区对临床研究的低水平认识和参与的关注。在美国,有多达100万人患有帕金森症,但只有不到1%的人参加了临床研究,这远远低于研究人员预计在未来两到三年内需要的志愿者人数。2005年10月,PDtrials活动启动了一系列在线营销策略,以提高www.PDtrials.org的知名度。这些措施包括开发每月的HTML电子邮件简报——PDtrials Bulletin,以及参与“病毒式”营销,例如将PDtrials Bulletin转发给整个社区的联系人。结果是,平均每日参观人次由2005年9月的465人次上升至2006年1月的822人次;整体参观人次由2005年9月的13,956人次上升至2006年1月的25,506人次。此外,超过50%的PDtrials Bulletin接收者打开电子邮件并从Bulletin点击到www.PDtrials.org。相比之下,非营利组织的行业标准是30%的打开率和3%的点击率。已经采用了各种策略来增加网站流量到www.PDtrials.org。最大的成功是通过在线培养那些要求获得有关临床研究信息并被认为感兴趣的个人。*PDtrials由帕金森病基金会牵头,与美国帕金森病协会、Michael J. Fox帕金森病研究基金会、国家帕金森基金会、帕金森病行动网络、帕金森联盟和WE MOVE合作。该运动由国家神经疾病和中风研究所(NIH)、帕金森研究小组、帕金森管道项目和帕金森研究所提供建议。
www.PDtrials.org: Increasing Parkinson’s Clinical Trial Awareness through the Internet
PDtrials⁎ is a national initiative dedicated to increasing education and awareness about clinical research by providing information to help people with Parkinson’s learn and make informed decisions about participating in clinical trials. www.PDtrials.org is a first-of-its-kind website that lists over 50 clinical studies seeking participants. It sees over 25,000 visits per month and has an email list of close to 2,500.
PDtrials was initiated in response to a concern within the Parkinson’s community about the low levels of awareness and participation in clinical research. As many as one million people in the U.S. live with Parkinson’s yet less than one percent participate in clinical studies—far short of volunteers that researchers anticipate will be needed over the next two to three years.
In October 2005, the PDtrials campaign initiated a series of online marketing strategies to increase visibility for www.PDtrials.org. These included the development of a monthly HTML email newsletter—the PDtrials Bulletin and engaging in “viral” marketing, such as forwarding the PDtrials Bulletin to contacts throughout the community.
The results were an increase in average daily visitors from 465 in September 2005 to 822 in January 2006 and an increase in overall visits from 13,956 in September 2005 to 25,506 in January 2006. In addition, over 50% of PDtrials Bulletin recipients opened the email and clicked through from the Bulletin to www.PDtrials.org. This compares with a nonprofit industry standard of a 30% open rate and 3% click-through rate.
Various strategies have been employed to increase web traffic to www.PDtrials.org. The greatest success has been through online cultivation of individuals who have requested to receive information about clinical studies and who are thought to be interested.
*PDtrials is led by the Parkinson’s Disease Foundation in collaboration with the American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson’s Research, the National Parkinson Foundation, the Parkinson’s Action Network, The Parkinson Alliance and WE MOVE. The campaign is advised by the National Institute of Neurological Disorders and Stroke (NIH), the Parkinson Study Group, the Parkinson Pipeline Project and the Parkinson’s Institute.